Green Elephant Biotech — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Green Elephant Biotech is a private, pre-revenue platform company pioneering hardware and consumable solutions for adherent cell manufacturing. Its core technologies, the CellScrew® culture vessel and the Archimedes® One dynamic bioreactor, are designed to simplify, intensify, and automate the scale-up from R&D to GMP clinical manufacturing. The company targets the rapidly growing cell and gene therapy and biologics markets by addressing key bottlenecks in space, labor, and process complexity, positioning itself as an enabler for more accessible and sustainable therapeutics.

Synthetic BiologyBiologics

Technology Platform

Proprietary adherent cell culture platform featuring the CellScrew® high-surface-area culture vessel and the Archimedes® One dynamic bioreactor for scalable, automated manufacturing of cell therapies, vaccines, and biologics.

Opportunities

The rapid growth of the cell and gene therapy market, which is heavily reliant on adherent cell cultures, creates a massive demand for scalable and cost-effective manufacturing solutions.

Increasing pressure on biopharma to reduce production costs and facility footprints aligns perfectly with Green Elephant's value proposition of space and labor savings.

Risk Factors

The primary risk is slow adoption by a conservative industry hesitant to change core manufacturing processes.

The company also faces competition from large, established bioprocess equipment vendors and must successfully execute the complex transition from developer to reliable GMP supplier.

Competitive Landscape

Green Elephant competes with large bioprocess conglomerates (e.g., Sartorius, Thermo Fisher) offering traditional microcarrier and flask-based systems, as well as specialized CGT tool companies. Its differentiation lies in the unique CellScrew® design for process intensification and its integrated path from research to GMP via a single consumable format.

More companies in Biologics / Biosimilars →More companies in Germany →